Novocure Announces 55 Presentations at European Association of Neuro-Oncology Meeting 2018

NovoCure (NASDAQ: NVCR) announced today 55 presentations on Tumor
Treating Fields at the European Association of Neuro-Oncology (EANO)
Meeting 2018, Oct. 10 through Oct. 14, in Stockholm. Tumor Treating
Fields is a cancer therapy that uses electric fields tuned to specific
frequencies to disrupt cell division, inhibiting tumor growth and
causing affected cancer cells to die. The volume of Tumor Treating
Fields presentations marks a record number of abstracts for Novocure at
this conference.

Highlights include a retrospective data analysis from Novocurea??s EF-14
phase 3 pivotal trial in newly diagnosed glioblastoma (GBM) that
demonstrated an increased dose of Tumor Treating Fields to the tumor bed
improved overall survival in GBM patients; and safety data on the use of
Tumor Treating Fields as a treatment for GBM from a surveillance study,
supporting EF-14 trial results.

Novocure also will host a scientific lunchtime symposium on Tumor
Treating Fields at the meeting.

"We continue to evaluate the data from our EF-14 trial and apply what we
learn to the development of Tumor Treating Fields,a?? said Dr. Eilon
Kirson, Novocurea??s Chief Science Officer and Head of Research and
Development. "The focus on Tumor Treating Fields at scientific
conferences continues to grow each year, demonstrating an increased
interest in our therapy among the scientific community. We are proud of
the work we have done to generate increased awareness of the potential
benefits of Tumor Treating Fields with the scientific community and look
forward to presenting at the EANO Meeting.a??

Oral Presentation

(OS5.5) Surveillance data demonstrates the tolerability of tumor
treating fields in pediatric glioma patients. A. Kinzel. 12:03 to 12:15
p.m. CEST Saturday, Oct. 13.
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Июль 2020    »